A randomized, open-label, two-treatment, four-period, two-sequence, single-dose, balanced, crossover, comparative pharmacokinetic study of CPL20090031 Tablets 140mg of Cadila Pharmaceuticals Ltd, India with JANUVIA (Sitagliptin) Tablets 100mg of MSD Pharmaceuticals Limited, India in healthy, adult human subjects under fasting and fed condition.
Latest Information Update: 09 Nov 2020
At a glance
- Drugs CPL 2009-0031 (Primary) ; Sitagliptin
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors Cadila Pharmaceuticals
Most Recent Events
- 04 Nov 2020 Status changed from recruiting to active, no longer recruiting.
- 29 Jan 2020 New trial record